Celgene Names New CEO and COO

From DCAT Value Chain Insights (VCI)

By People On The Move posted 01-12-2016 14:29


Celgene Corporation, has made several organizational changes, effective March 1, 2016. Mark Alles, currently president and chief operating officer (COO) will be promoted to chief executive officer (CEO) and Jacqualyn Fouse, currently president, global hematology and oncology, will be promoted to president and COO. Robert Hugin, currently chairman and CEO, will continue to serve as executive chairman and lead the board of directors and manage the strategic direction of the company. In addition, Scott Smith, president, immunology & inflammation (I&I), will assume an expanded leadership role.

Alles is a three-decade industry veteran and has been with Celgene since 2004, most recently serving as president & COO. In this role, he integrated Celgene's corporate operational functions in support of its global commercial franchises. Before serving as president & COO, he built and led Celgene's hematology & oncology franchise,

Fouse Celgene in 2010 as chief financial officer. As president and COO, Jackie will focus on further enhancing Celgene's commitment to operational excellence, driving exceptional performance across Celgene's franchises and functions. Reporting to her in this role will be Celgene's corporate operational functions as well as the hematology & oncology and I&I franchises.

Scott Smith, president of Celgene's I&I franchise, will be appointed to chair Celgene's Global Management Committee. As Chair of Celgene's Global Management Committee, he will be responsible for the effective coordination of Celgene's operational and strategic imperatives. Scott joined Celgene in 2008 and will continue to be responsible for building and leading Celgene's I&I franchise.

Source: Celgene


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription